Nootropics Raw Agomelatine Powder Pharmaceutical Agomelatine

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Agomelatine
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Agomelatine
• Name: Agomelatine Powder
• Assay: HPLC 99%
• Appearance: White Powder
• Color: White
• CAS No.: 138112-76-2
• Mf: C15h17no2
• MW: 243.3
• Melting Point: 107-109°c
• Boiling Point: 478.8
• Density: 1.109
• Test Method: HPLC
• Grade: Pharmaceutical Grade
• Application: Nootropics; Anti-Depression
• Specific: COA
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Nootropics Raw Agomelatine Powder Pharmaceutical Agomelatine 

Product Description

Product Details

Product Name	Agomelatine
Appearance	White Powder
CAS No.	138112-76-2
MF	C15H17NO2
MW	243.3

Agomelatine is the world's first melatonin receptor MT1 and MT2 agonist antidepressant, suitable for treating severe depressive episodes in adult patients. We know that melatonin is an endogenous neurohormone secreted only by the anterior pituitary gland of the pineal gland at night, and acts on melatonin receptors concentrated in the suprachiasmatic nucleus (SCN) of the hypothalamus, participating in the regulation of mammalian circadian rhythms. It is a well-known time guardian in the body, correcting the biological clock regulated by the external circadian cycle. However, due to its high metabolic rate in the body, melatonin has a short half-life and poor selectivity for its receptors located in the SCN, which limits its use in the treatment of circadian rhythm disorders. Therefore, to overcome these deficiencies of melatonin, researchers have designed a series of melatonin analogs. Molecular modeling studies have shown that the indole ring of melatonin is the structural site for its catabolic inactivation, making it an ideal site for electron isomorphic modification. Agomelatine, developed by Schweria, is an electronic analogue of melatonin. It replaces the indole ring with nucleus, making it more metabolically stable than melatonin.

Application&Function

The launch of agomelatine is a new breakthrough in the field of depression treatment. It is both a melatonin MT1/MT2 receptor agonist and a serotonin 2c (5-HT2C) receptor antagonist. Through the synergistic effect of the two, it restores the disrupted circadian rhythm of patients with depression and produces antidepressant efficacy. Its unique mechanism of action opens up an innovative approach to treating depression. The mechanism of action of agomelatine is completely different from commonly used antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs): SSRIs and SNRIs are antidepressants that achieve antidepressant efficacy by increasing serotonin concentration, but this also brings many side effects, such as weight changes, sexual dysfunction, withdrawal syndrome, etc. The drug molecule structure of agomelatine directly binds to the 5-hydroxytryptamine 2c (5HT2c) receptor on the postsynaptic membrane of the nervous system, thereby exerting its antidepressant effect without increasing the concentration of 5-hydroxytryptamine in the synaptic cleft. This unique mechanism of action enables agomelatine to rapidly and effectively exert its antidepressant efficacy while minimizing the occurrence of drug side effects. Another unique target of agomelatine is the melatonin receptor. The MT1MT2 receptor is densely distributed in the suprachiasmatic nucleus of humans, which mainly controls the sleep rhythm of humans. By stimulating the MT1MT2 receptor, agomelatine effectively improves the sleep quality of patients and enhances their daytime wakefulness. There is a mutually causal relationship between the quality of sleep and the outcome of depression. According to reports, 80% of patients with depression have varying degrees of sleep disorders. The improvement of sleep quality directly promotes the overall clinical condition of patients with depression. It's a melatonin drug.

Specification